The current paradigm for studying hepatitis C virus (HCV) dynamics in patients utilizes a
standard viral dynamic model that keeps track of uninfected (target) cells, infected cells, and …

Hepatitis C virus (HCV) infections are a global health problem, and extensive research over
the last decades has been targeted at understanding its molecular biology and developing …

The nonstructural 5A (NS5A) protein is a target for drug development against hepatitis C
virus (HCV). Interestingly, the NS5A inhibitor daclatasvir (BMS-790052) caused a decrease …

Chronic hepatitis C virus (HCV) infection remains a world-wide public health problem.
Therapy with interferon and ribavirin leads to viral elimination in less than 50% of treated …

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease and affects nearly
170 million people worldwide. Whereas the previous standard of care with pegylated …

Direct-acting antivirals (DAAs) treat hepatitis C virus (HCV) by targeting its intracellular viral
replication. DAAs are effective and deliver high clinical performance against HCV infection …

The current paradigm for modeling viral kinetics and resistance evolution after treatment
initiation considers only the level of circulating virus and cellular infection (CI model), while …

We propose an integrative, mechanistic model that integrates in vitro virology data,
pharmacokinetics, and viral response to a combination regimen of a direct-acting antiviral …

Hepatitis C virus (HCV) infection is a global health problem, with nearly 2 million new
infections occurring every year and up to 85% of these infections becoming chronic …

By mathematically describing early hepatitis C virus (HCV) RNA decay after initiation of
interferon (IFN)‐based antiviral therapy, crucial parameters of the in vivo viral kinetics have …